A key issue in vaccine development is balancing immunogenicity with safety and vaccine safety gets more public attention than vaccine efficacy. Many of the successful vaccines we have today are based on live-attenuated or inactivated pathogens or live vectors such as non-replicating bacteria or viruses that induce robust antibody and cellular immunity. However, antivector immunity and safety concerns associated with live vectors complicate their use in infants and aged populations and in people with immunocompromised systems. Our lab is interested in the development of nano-scale biomaterials such as nanofibers, nanoparticles, virus-like particles, and hydrogels for engaging the immune system to induce protective antibody and cell-mediated immune responses against diseases such as tuberculosis, melanoma, and flavivirus infections (West Nile and Zika). We are also investigating the development of vaccines against drugs of addiction such as cocaine. Biomaterials immunoengineering is a multidisciplinary field that lies at the intersection of materials science, chemistry, immunology, and vaccinology. We collaborate with virologists, immunologists, and clinicians not only to develop synthetic vaccination platforms but also to understand how biomaterials interact with the immune system and continue to develop novel materials and creative tools to tackle multidisciplinary problems in vaccine development and immunotherapy.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.